

- Service de Réanimation Médicale, Hôpital Européen Georges Pompidou, Assistance Publique
- Hôpitaux de Paris, Paris, France
- <sup>8</sup> INSERM UMR S1140, Université Paris Descartes, Paris Sorbonne Cité, Paris France
- <sup>9</sup> Service de Réanimation, Hôpital Antoine Béclère, Assistance Publique - Hôpitaux de Paris,
- Clamart, France
- <sup>10</sup> Service de Réanimation, Hôpital Raymond Poincaré, Assistance Publique Hôpitaux de
- Paris, Garches, France
- <sup>11</sup> Université Versailles Saint-Quentin, Versailles, France
- <sup>12</sup> Service de Réanimation Chirurgicale, Hôpital Européen Georges Pompidou, Assistance
- Publique Hôpitaux de Paris, Paris, France
- <sup>13</sup> BioMérieux SA, Lyon, France
- <sup>14</sup> Unité de Biostatistiques et d'Epidémiologie, Hôpital Cochin, Assistance Publique Hôpitaux
- de Paris, Paris, France
- <sup>15</sup> Université de Paris, Paris, France
- 
- **\***Corresponding author:
- ORCID iD : 0000000164660065
- e-mail: [benoit.misset@chuliege.be](mailto:benoit.misset@chuliege.be) (BM)
- 
- **Authors' contributions:**

- Drs Misset, Philippart, Cavaillon and Coste had full access to all the data in the study and take
- responsibility for the integrity of the data and the accuracy of the data analysis.
- Study concept and design: Misset, Philippart, Cavaillon and Coste
- Acquisition of data: Philippart, Fitting, Parlato, Moucadel, Bedos, Journois, Hamzaoui,
- Annane, Diehl
- Access to data, analysis and interpretation: Misset, Philippart, Parlato, Moucadel, Cavaillon and
- Coste
- Drafting of the manuscript: Misset, Philippart, Cavaillon and Coste
- Critical revision of the manuscript for important intellectual content: Misset, Philippart,
- Annane, Moucadel, Cavaillon and Coste
- Statistical analysis: Coste
- Obtained funding: Misset, Moucadel
- Administrative, technical, or material support: Fitting
- 
- 
- ^Members of the Combined Approach for The eArly diagnosis of INfection in sepsis
- (CAPTAIN) study group is provided in the Acknowledgments (collaborators section).

## **Abstract**

## **Background**

 Although sepsis is a life-threatening condition, its heterogeneous presentation likely explains the negative results of most trials on adjunctive therapy. This study in patients with sepsis aimed

to identify subgroups with similar immune profiles and their clinical and outcome correlates.

#### **Methods**

 A secondary analysis used data of a prospective multicenter cohort that included patients with early assessment of sepsis. They were described using Predisposition, Insult, Response, Organ failure sepsis (PIRO) staging system. Thirty-eight circulating biomarkers (27 proteins, 11 mRNAs) were assessed at sepsis diagnosis, and their patterns were determined through principal component analysis (PCA). Hierarchical clustering was used to group the patients and *k*-means algorithm was applied to assess the internal validity of the clusters.

## **Results**

 Two hundred and three patients were assessed, of median age 64.5 [52.0-77.0] years and SAPS2 score 55 [49-61] points. Five main patterns of biomarkers and six clusters of patients (including 42%, 21%, 17%, 9%, 5% and 5% of the patients) were evidenced. Clusters were distinguished according to the certainty of the causal infection, inflammation, use of organ support, pro- and anti-inflammatory activity, and adaptive profile markers.

### **Conclusions**

 In this cohort of patients with suspected sepsis, we individualized clusters which may be described with criteria used to stage sepsis. As these clusters are based on the patterns of  circulating biomarkers, whether they might help to predict treatment responsiveness should be addressed in further studies.

#### **Trial registration**

82 The CAPTAIN study was registered on clinicaltrials.gov on June 22, 2011, # NCT01378169.

## **Introduction**

 Sepsis is a clinical picture of organ dysfunctions elicited by an infection, and associated with immune dysregulation [1]. Its mortality varies between 25 and 60 % [2, 3]. The intensity of the organ dysfunctions are usually assessed by the SOFA score [4]. Immune dysregulation is complex and not fully deciphered [5], follows from the activation by both pathogen and danger- associated molecular patterns [6], and is associated with a variety of immune pathways including inflammation, compensatory anti-inflammation, and low adaptive profile [7, 8]. It is likely dependent on underlying diseases [9], genetic predisposition [10] and the causal agent of infection [11]. All these dimensions of sepsis are included in the Predisposition, Insult, Response, Organ failure sepsis (PIRO) classification system, a tool proposed in 2001 to characterize and stage sepsis [12]. As numerous trials failed to improve unselected cohorts of patients with sepsis [13, 14], "endotypes" describing patient groups with similar genetic, epigenetic or proteomic pattern, have been proposed [15]. They are excepted to help to predict treatment responsiveness and not just differences in prognosis [16]. Endotyping aims at categorizing the different pathways involved [14, 16] in order to select patients as potential targets of specific treatments [17, 18]. Data on endotypes are scarce because the collection of many biomarkers is not available in daily routine [19]. To comply with the recommendations of the surviving sepsis campaign [3], sepsis must be suspected and treated before the infection is confirmed, and biomarkers might help to differentiate patients with bacterial infection from  those with other causes of immune dysregulation [20]. A better understanding of subgroups within the heterogeneous host response to infection is important both for a better understanding of the biology of sepsis but also for the next generation of trials of more precise interventions for sepsis.

 In a multicenter prospective cohort called CAPTAIN that included patients with suspected sepsis for whom circulating proteins or mRNAs from circulating leukocytes were assessed, these biomarkers were not able to discriminate patients with *versus* without a documented causal infection [21]. Then, we hypothesized that a clustering approach may help defining subgroups of similar patients in multidimensional populations.

 In the present study, using the same cohort of patients with sepsis, we aimed at identifying homogeneous subgroups in terms of circulating biomarkers, and clinical phenotypes and mortality correlates.

## **Methods**

### **Study design**

 This study is a secondary analysis of the observational multicenter prospective CAPTAIN study (Combined Approach for The eArly diagnosis of INfection in sepsis) [21]. It was designed and conducted according to STROBE (STrengthening the Reporting of OBservational studies in Epidemiology) guidelines (S1 Table) [22].

## **Ethics and study registration**



## **Setting**

 Patients were recruited from December 2011 to April 2013 in seven ICUs from five hospitals in Paris area.

#### **Participants**

 Eligible ICU patients were those patients with suspected sepsis. The inclusion criteria were 136 hypothermia (below 36.0 $^{\circ}$ C) or hyperthermia (over 38.0 $^{\circ}$ C), and at least one criterion of systemic inflammatory response syndrome (SIRS) [12] as soon as the physician considered antibiotic therapy. Other inclusion criteria were age over 18 years, no treatment limitation and no obvious immunosuppression.

 Demographics, reasons for ICU admission, underlying diseases, simplified acute severity score (SAPS 2) [20], physiological data, Sequential Organ Failure Assessment (SOFA) score [21] and length of organ failure support were collected at admission to the ICU, at inclusion in the study and over the ICU stay. The population characteristics have been published previously [21]. Briefly, 363 patients were screened and 279 included. Based on the data obtained in the 72 hours after inclusion, infection could not be ascertained in one third of the patients after  adjudication by two investigators who were blind to the biomarkers. The biomarkers were found to discriminate poorly between patients with *versus* without a documented causal infection [21]. The present analysis focused on those patients who were still in ICU after day 3, because we wanted to describe their clinical phenotypes during at least the first three days of the syndrome. We excluded those patients having not at least one available value for all the 38 biomarkers collected in the first two days of inclusion because principal component analysis (see below) does not handle with missing data, leading to 203 patients available for analysis. All included patients had a recent increase of the total SOFA score and fulfilled the characteristics of the Sepsis-3 definition [1] despite being included before its publication.

#### **Biomarkers assessment**

 We collected whole blood samples at day 0 and 1 of inclusion to assess 38 biomarkers, reported as potential indicators of infection or mortality during sepsis [23]. They were measured using various techniques: ELISA for galectin, peptidoglycan, visfatin (previously known as pre-B cell colony-enhancing factor (PBEF), soluble B7-H6 (sB7-H6), soluble Triggering Receptor Expressed on Myeloid cells-1 (sTREM-1), soluble urokinase-type Plasminogen Activator Receptor (suPAR) and Pancreatic Stone Protein (PSP); Bioplex technique for C-Reactive Protein (CRP), ferritin, Granulocyte-Colony Stimulating Factor (G-CSF), chemokines: GRO alpha (GRO-α/CXCL1), Monocyte Chemo-attractant Protein 1 (MCP-1/CCL2), Macrophage Inflammatory Protein-1 alpha (MIP-1α/CCL3), Macrophage Inflammatory Protein-1 beta (MIP-1β/CCL4), Regulated upon Activation Normal T-cell Expressed and Secreted (RANTES/CCL5), IFN-γ-induced protein 10 (IP-10/CXCL10); Interferon gamma (IFN-γ), Interleukin-1 Receptor antagonist (IL-1Ra), Interleukins 6, 8, 10, 15, and 18 (IL-6, IL-8, IL-10, IL-15 and IL-18), Macrophage-Colony Stimulating Factor (M-CSF), Macrophage Migration

 Inhibitory Factor (MIF), Matrix Metallo Proteinase-8 (MMP-8), Procalcitonin (PCT), and Tumor Necrosis Factor (TNF); and Real Time quantitative Polymerase Chain Reaction (RT- qPCR) for the following whole blood mRNAs: Cluster of Differentiation 3δ and 74 (CD3D and CD74), CX3 chemokine receptor 1 (CX3CR1), Human Leucocyte Antigen DR-alpha chain (HLA-DR), High Mobility Group Box 1 protein (HMGB1), IL-1β, IL-10, Leukocyte Immunoglobulin-Like Receptor subfamily B member 2 (LILRB2), S100 calcium-binding protein A9 (S100A9) and TNF. Of these biomarkers, IL-1Ra, IL-10 and IL-10 mRNA are considered as anti-inflammatory, HLA-DR mRNA, CD74 mRNA, CD3 mRNA and LILRB2 mRNA as markers of adaptive immunity, and peptidoglycan as a pathogen-associated molecular pattern. All other above-mentioned biomarkers are considered as mediators or markers of inflammation.

 Plasma (EDTA) was prepared at reception, aliquoted and frozen. Concentrations of plasma markers were determined at the end of the study by sandwich ELISA or by Multiplex analysis according to manufacturers' recommendations (S2 Table). All the plasma and cell surface markers were purchased from providers, except Soluble B7-H6 (S2 Table). All primers and probe for the RNA markers were designed internally and purchased from Eurogentec. However, primers and probe (different designs) can also be bought from some providers like ThermoFisher. Limits of quantification are provided in S3 Table. For biomarkers whose value 188 was below the lower limit of quantification (LLoQ), we attributed a value of LLoQ /  $\sqrt{2}$ . For biomarkers whose value was over the upper limit of quantification (ULoQ), we attributed the ULoQ value. The distribution of missing values and determination of the cut-off to create binary variables are provided in S1 Fig. PAXgene® blood samples were incubated at room temperature for 2 hours before freezing. RNA was extracted using the PAXgene® blood RNA kit (PreAnalytix) and frozen at -80°C. Two hundred nanograms RNA were reverse transcribed (RT) using the SuperScript® VILO™ cDNA Synthesis Kit (Life Technologies) at the end of

 the study. A RNA calibrator made from PAXgene® samples collected from a pool of healthy volunteers and stimulated *ex vivo* by LPS was used in each RT run. cDNA was then diluted at 1/20 and stored at -20°C. Polymerase Chain Reaction (PCR) was performed on a LightCycler instrument using the standard Taqman Fast Advanced Master Mix PCR kit according to the manufacturer's instructions (Roche Molecular Biochemicals). Thermocycling was performed in a final volume of 20 μL containing 0.5 μM of primers and 0.1 μM of probe (see primer and probe designs in S4 Table). PCR was performed with an initial denaturation step of 10 min at 202 95°C, followed by 45 cycles of a touchdown PCR protocol (10 sec at 95°C, 29 sec annealing with 68°C for the first cycle and decrease of 0.5°C for each cycle until reaching 58°C, and 1 sec extension at 72°C). The Second Derivative Maximum Method was used by the LightCycler software to automatically determine the crossing point (cycle threshold, Ct). Ct were converted to Calibrated Normalized Relative Quantity (CNRQ) taking HPRT1 and PPIB as reference genes [24].

## **Clinical phenotypes description**

 We described the patients clinical phenotypes according to the PIRO classification system [12, 25] where predispositions (P) related with chronic status and disease, insult (I) with the cause 212 of the suspected sepsis, response (R) with clinical response to this cause, and organ dysfunction (O) with the nature and severity of the organ dysfunctions. P items were age, gender, body mass index (BMI), Mac Cabe score, chronic lung, cardiac, renal or hepatic insufficiencies, diabetes or malignancy. I items were bacterial infection of the lung, abdomen or urinary tract. R items were body temperature, blood lymphocyte and platelet counts, prothrombin time and serum lactates as indicators of inflammatory response, coagulation activation and tissue hypoxia; pneumonia or bacteremia occurring after day 5 of the ICU stay as indicators of immune

 dysfunction. O items were sequential organ failure assessment (SOFA) and each of its sub- components (respiratory, nervous, cardiovascular, liver, coagulation and kidney dysfunctions) within two days of inclusion. Outcome was defined as the mortality at the end of the ICU stay. Infections were confirmed *a posteriori*, based on criteria which confirm infection as much as possible, either with or without positive cultures. The definition of infection and its causal link with organ dysfunction required medical interpretation [26] and were based on IDSA guidelines [27]. They were adjudicated blindly to the studied biomarkers, by two investigators (FP and BM). They reviewed the patients'' records, including clinical history, results of routine morphologic, biological, or microbiological tests, and response to therapies during the days following inclusion. Strains were considered as infecting, colonizing or contaminants. Infection could be considered as present despite the absence of a positive microbiological sample, for example in cases of abscess or pneumonia [27]. When bacteremia was present, it was linked to most probable anatomical focus of infection. Viruses were only searched in case of Influenza suspicion and were classified as non-septic SIRS. Disagreements on classification were resolved after discussion between the two adjudicators.

#### **Statistical analysis**

 The determination of classes in numerical taxonomy is generally achieved by cluster analysis of a resemblance matrix, which is a combination of similarities (or distances) between all pairs of objects, *e.g.* patient's biomarkers. Here, such a simple process appeared inadequate because of the large and heterogeneous scales of biomarkers involved. Transformation and reduction of data were necessary. After adequate transformation of the data, we therefore performed a first  factor analysis and further used a number of standardized factor scores for each individual as input (in the resemblance matrix) to the clustering method.

#### **Data transformation**

 We determined the maximum value of the blood levels (Cmax) obtained at day 0 and day 1 of inclusion for each biomarker. For all biomarkers, these values were log-transformed to normalize their distribution and further standardized to mean 0 and unit variance.

## **Principal component analysis**

 To evidence patterns, Cmax of biomarkers were used to build correlation matrices (Pearson coefficients), then studied by principal component analysis (PCA), followed by varimax rotations of retained components. The patterns obtained were uncorrelated linear combinations of normalized and standardized biomarkers, and sorted by decreasing variance of rates explained, whose coefficients, the "loadings", are interpretable as correlation coefficients between patterns and original biomarkers. These loadings help identify the "nature" or 257 "meaning" of the patterns: "loadings"  $> 0.40$  are usually considered to indicate substantial *correlation*. The number of components-patterns to retain was determined by the Horn and Velicer methods as recommended [28].

## **Clustering**

 The scores of the patients on the components-patterns retained were selected for cluster analysis. Hierarchical cluster analysis (Ward method) was used to obtain the initial cluster  grouping because of the lack of *a priori* knowledge of the number of clusters involved. The number of clusters selected was based on standard statistical criteria (optimal values of R2, pseudo-F, pseudo-t2 and cubic clustering criterion, which all reflect some balance between within and between cluster variances), as recommended [29].

#### **Cluster internal validity**

 Two methods were used to evaluate the stability and the replicability of the hierarchical cluster solution; (1) a *k*-means algorithm: this method does not assume a hierarchical relationship among clusters and allows for relocation of cases throughout the clustering process (reducing the risk of misassignment common to hierarchical cluster method [29]); (2) a subsample analysis: the hierarchical cluster analysis was repeated with a random 50% sample of the initial population to investigate whether subjects clustered similarly when they were distributed in subsamples [30].

#### **Description of the clusters**

 The clusters obtained were finally compared for each individual circulating biomarker and for the clinical variables usually used to describe patients with sepsis. These variables were classified according to the different categories of the PIRO system to facilitate reading and interpretation. For each phenotype qualitatively described, we defined two groups of patients according to its presence or absence. We compared the proportions of patients in each cluster with these phenotypes using non-parametric Fisher exact test. For each phenotype defined with a quantitative value, we assessed correlations of the phenotype with each cluster using a Spearman rank test and we compared the values of each phenotype within each cluster using

 Kruskall-Wallis statistics. The quantitative values are displayed as median [Q1-Q3] and the 288 qualitative values as  $n$  (%). We considered a p-value below 0.05 for statistical significance. SAS 9.4 package was used for all analysis (SAS Inst., Cary, NC, USA). 

**Results**

#### **Patients**

 Out of 363 patients screened for biomarkers, 279 patients were included in the Captain cohort, but 33 died or were discharged from the ICU before day 3, leading to 246 eligible patients. Of these, 43 had a least one missing value among the 38 biomarkers, leading to 203 evaluable patients (Fig 1). The population characteristics according to the PIRO system, are reported in Table 1. Their median age was 64.5 [52.-77.0] years, median SAPS II score, 55 [49-61] points, and they were included 23 [11-45] hours after ICU. Among them, 189 (77%) were in the ">5- year life expectancy" category of the Mac Cabe score, 116 (47%) had underlying diseases, the suspected infection was confirmed for 171 (70%). After day 5 of ICU, 26 (13%) had acquired pneumonia and 8 (4%) bacteremia. Mechanical ventilation, vasopressors, renal replacement therapy and low-dose steroids were used in 182 (74%), 95 (38%), 19 (8%) and 22 (9%) patients, respectively, and 58 (29%) patients died in the ICU. The levels of each single biomarker for the total cohort have been published previously [21].

**Fig 1. Flowchart**

#### 308 **Table 1 : Characteristics of the patients, organized according to the PIRO system and**

#### 309 **outcome**







#### **Patterns of circulating biomarkers and clusters of patients**

 PCA of the 38 biomarkers provided five main components-patterns, which explained 30.7%, 9.7%, 8.0%, 5.5% and 4.7% (total 58.6%) of the variance, respectively. The biomarkers with a 314 high loading ( $\vert$ loading $\vert > 0.40$ ) are displayed in S5 Table. Pattern #1 gathers circulating biomarkers and mRNAs linked to both pro- and anti-inflammatory response and to altered immunity. Pattern #2 gathers only circulating biomarkers associated with pro- and anti- inflammatory response, and shares numerous cytokines and chemokines with pattern #1 (i.e., IL-1Ra, IL-6, IL-8; MCP-1, G-CSF, GM-CSF, and MIP-1β). Pattern #3 gathers only mRNA markers linked to both pro- and anti-inflammatory response. Pattern #4 displays specific biomarkers not shared with any other clusters (i.e., Galectin-9, SuPAR, MIF, and Ferritin). Similarly, pattern #5 has its specific biomarkers (RANTES, sTREM-1). These 5 patterns allowed to build 6 clusters of patients with homogeneous biological profiles. The S6 Table displays the scores of the 5 patterns within each cluster of patients. The use of a *k*-means algorithm (non-hierarchical method), with the number of clusters set to 6, led to similar 325 clustering as with the Ward method, with satisfactory agreement (Carmer's  $V = 0.63$ ). Similar 326 clustering solutions were found with analysis of a random 50% of the sample (Cramer's  $V =$ 0.59). These results support the robustness of the six clusters.

 The Table 2 shows the criteria of the PIRO profile of sepsis. "Predisposition" items of the PIRO system differed moderately across clusters. Among the "insult", "response", and "organ failure" categories, the most different items between clusters were infection certainty, blood lactate

 levels, serum creatinine levels, urinary output, survival, circulatory and renal SOFA sub-scores, and use of renal replacement therapy, vaso-pressors and steroids. The Table 3 shows that the levels of the 38 individual circulating biomarkers differed markedly across the clusters and that biomarkers of the same category (pro-inflammatory, anti-inflammatory, adaptive immunity) displayed consistent values within each cluster. In these tables, the color code (from dark red to high level, to dark blue for low level) illustrates the differences within each item of the clusters. Based on these comparisons, six clusters can be distinguished according to the certainty level of the causal infection, the existence of inflammation, use of renal and/or hemodynamic support, pro-inflammatory and anti-inflammatory activity, and markers of adaptive profile. Four clusters (clusters #2, #3, #4 and #6) were associated with high mortality (> 30%) and a low adaptive profile (Table 2), and represented 53% of the cohort (Fig 2). Clusters #2 and #6 exhibited both high levels of inflammatory and anti-inflammatory mediators, but differed with regards to CRP and ferritin, #3 displayed anti-inflammatory mediators at low level, and #4 displayed both inflammatory and anti-inflammatory mediators at low level (Fig 2).

 **Fig 2. Distribution and description of the clusters in the cohort.** All the clusters display different characteristics in terms of parameters of the PIRO system, of circulating biomarkers and outcome.



## 350 **Table 2 : Value of each clinical criterion of the PIRO profile of sepsis and outcome in each cluster**





351 The clinical criteria are sorted according to the PIRO classification system. In each raw, the dark red color indicates the highest value and dark

352 blue color indicates the lowest value, for those variables which are the most significantly different across the clusters.



## 354 **Table 3 : Value of each circulating biomarker of sepsis in each cluster.**



355 The individual biomarkers are sorted according to their role in inflammation, anti-inflammation or adaptive immune profile. In each raw, the dark

356 red color indicates the highest value and dark blue color indicates the lowest value. CNRQ = Calibrated Normalized Relative Quantity

## **Discussion**

 In a prospective cohort of ICU patients suspected of sepsis, through the levels of circulating biomarkers indicative of pro-inflammation, anti-inflammation or adaptive immunity and the use of unsupervised statistical approaches, we individualized six different clusters of patients with homogeneous profiles regarding sepsis clinical staging. These clusters presented with different immune and clinical profiles, making them potential targets for individualized therapies.

 Sepsis is a life-threatening condition elicited by various infectious conditions, with a heterogeneous presentation, and an outcome impacted by both the pathogen and host characteristics [1]. This phenotypic polymorphism led to the proposal of the PIRO classification and staging system in 2001 to help individualize future therapies [12]. A better understanding of subgroups within the heterogenous host response to infection is important both for a better understanding of the biology of sepsis but also for the next generation of trials of more precise interventions for sepsis.

 Given the heterogeneity of both clinical and immune presentation of sepsis and the multiple failures of trials in unselected populations [13], a cluster approach has been used by several authors [31]. In these studies, clustering was based either on phenotypes to describe different clinical profiles without addressing immune mechanisms of sepsis, and mostly provide differences in prognosis, or on endotypes, deriving subclasses from genome-wide expression profiling [31]. The latter option, as endotypes are markers of pathophysiological pathways, may help to predict treatment responsiveness [16]. Wong *et al.* identified three pediatric septic shock subclasses named A, B and C [32]. Subclass A displayed a depressed expression of adaptive immune system, of glucocorticoid signaling and zinc-related biology and associated with higher severity and mortality. Scicluna *et al.* identified four sepsis subclasses named Mars 1 to 4 [15].

 Subclass Mars1, with a higher mortality, displayed reduced expression of genes involved in innate and immune functions. Subclass Mars3, with a better survival, displayed increased expression of adaptive immune or T-cell functions. Davenport *et al.* identified two sepsis subclasses named SRS1 and SRS2 [33], with SRS1 characterized by a higher mortality and decreased expression of immune functions. Finally, based on gene activation profiles, Sweeney *et al.* identified three sepsis subclasses named inflammopathic, adaptive and coagulopathic [34]. The adaptive subgroup was associated with lower severity and mortality, and the coagulopathic subgroup with higher mortality and clinical coagulopathy. In our study, we also derived clusters from endotypes, but these were assessed with biomarkers made of molecules previously documented to play a role the pathophysiology of sepsis. We used unsupervised statistical approaches to set up clusters, because they explore data without *a priori* classification [35]: principal component analysis, to determine different patterns, hierarchical clustering to group the patients and *k*-means algorithm to assess the internal validity of the clusters.

 In our cohort, two clusters (#1 and #5) had a low level of organ dysfunction and mortality. Clusters #2 and #3 displayed high level of infection certainty and inflammation, and differed by their anti-inflammatory status, consistent with the concept of compensatory anti- inflammation and its heterogeneity [8]. Cluster #4 displayed a low level of innate response despite high severity and high ferritin levels. Lastly, two clusters, #5 and #6, were associated with very specific phenotypes, one (#5) with pro and anti-inflammatory high-level profile despite low mortality, and the second one (#6) with high immune alteration and particularly high level of ferritin.

 Half our cohort belongs to clusters associated with a high mortality rate. They are characterized by their low adaptive profile at sepsis diagnosis. They differ between themselves by their respective levels of certainty of the causal infection, of CRP and ferritin levels, of renal and hemodynamic level of support, and of pro-inflammatory and anti-inflammatory activities. Each

 of these characteristics may be available at bedside in parallel of the assessment of infection, organ dysfunction, pro- (for example TNFα and/or IL-18) and anti-inflammatory (for example IL-1Ra and/or IL-10) cytokines, and markers of adaptive function (for example HLA-DR). These criteria are relatively simple and should be validated in external cohorts before they can be used as inclusion criteria in prospective trials. Our study has limitations. First, several biomarkers, including some recently described, were

 not assessed in this cohort, and should be assessed in similar conditions. Especially, biomarkers more specific of endothelial dysfunction or coagulation activation were underrepresented in our panel. Second, although at risk of sepsis, several categories of patients were not included in the cohort, particularly those with prior immune suppression, whose innate and adaptive responses are likely different from the immunocompetent patients. These patients should be investigated using a similar approach. Third, while the generalizability of our study may be reinforced by its multicenter design and the use of internal validity assessments, we did not perform external validation in a separate cohort. This is particularly important for the groups with small numbers of patients in our cohort.

## **Conclusion**

 In a prospective cohort of ICU patients with suspected sepsis, we individualized clusters of patients which may be described with criteria commonly used to stage sepsis in routine practice. As these clusters are based on the patterns of circulating biomarkers, whether they might help to predict treatment responsiveness should be addressed in further studies.

## **Acknowledgements**

 We sincerely thank Drs Anne-Françoise Rousseau, Bernard Lambermont and François Jouret for their critical review, Céline Féger, MD (EMIBiotech) and Séverine Marck for their editorial support for this manuscript.

#### **Collaborators**

 Members of the Combined Approach for The eArly diagnosis of INfection in sepsis (CAPTAIN) study group:

 Sébastien JACQMIN, Didier JOURNOIS, Alix LAGRANGE, Gabrielle PINOT de VILLECHENON (*Hôpital Européen Georges Pompidou, AP – HP - Université Paris Descartes, Service d'Anesthésie-Réanimation),* Nadia AISSAOUI, Jean-Luc DIEHL, Emmanuel GUEROT, Marion VENOT (*Hôpital Européen Georges Pompidou, AP – HP - Université Paris Descartes, Service de Réanimation Médicale),* Olfa HAMZAOUI, Dominique PRAT, Benjamin SZTRYMF (*Hôpital Antoine Béclère, AP – HP - Université Paris Sud, Clamart),* Djillali ANNANE, Virginie MAXIME, Andrea POLITO *(Hôpital Raymond Poincaré, AP – HP - Université Paris Ile de France Ouest , Service de Réanimation Médico- chirurgicale)*, Belaïd BOUHEMAD, Cédric BRUEL, Frédéric ETHUIN, Julien FOURNIER, Maïté GARROUSTE-ORGEAS, Charles GREGOIRE, Nicolas LAU, Benoît MISSET, François PHILIPPART *(Groupe Hospitalier Paris Saint Joseph, Service de Réanimation),*  Jean-Pierre BEDOS, Pierrick CROSNIER, Virginie LAURENT, Sybille MERCERON (*Hôpital André Mignot, Versailles, Service de Réanimation médico-chirurgicale),* Elsa BOURNAUD, Laurence LECOMTE, Jean-Marc TRELUYER, *(Hôpital Cochin, AP-HP - Université Paris Descartes, Unité de Recherche Clinique),* Alexandre PACHOT, Javier

 YUGUEROS-MARCOS, Laurent ESTEVE, Sophie BLEIN, Virginie MOUCADEL (bioMérieux, Lyon & Grenoble), Myriam BEN BOUTIEB, Alexandra ROUQUETTE, Joël COSTE *(Hôpital Cochin, AP-HP - Université de Paris, Unité de Biostatistique et d'Epidémiologie)*, Minou ADIB-CONGUY, Jean-Marc CAVAILLON, Catherine FITTING, Marianna PARLATO, Virginie PUCHOIS, Fernando SOUZA-FONSECA-GUIMARAES (Institut Pasteur, Paris, Unit Cytokines & Inflammation).

## **References**

- 1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315:801–810.
- 2. Cecconi M, Evans L, Levy M, Rhodes A. Sepsis and septic shock. Lancet. 2018;392:75–87.

 3. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43:304–377.

 4. Vincent JL, de Mendonça A, Cantraine F, Moreno R, Takala J, Suter PM, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26:1793–1800.

 5. Rubio I, Osuchowski MF, Shankar-Hari M, Skirecki T, Winkler MS, Lachmann G, et al. Current gaps in sepsis immunology: new opportunities for translational research. Lancet Infect Dis. 2019;19:e422–e436.

- 6. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991– 1045.
- 7. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular
- dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13:862–874.
- 8. Adib-Conquy M, Cavaillon J-M. Compensatory anti-inflammatory response syndrome.
- Thromb Haemost. 2009;101:36–47.
- 9. Angus DC, Burgner D, Wunderink R, Mira J-P, Gerlach H, Wiedermann CJ, et al. The PIRO

concept: P is for predisposition. Crit Care. 2003;7:248–251.

- 10. Toubiana J, Courtine E, Pène F, Viallon V, Asfar P, Daubin C, et al. IRAK1 functional
- genetic variant affects severity of septic shock. Crit Care Med. 2010;38:2287–2294.
- 11. Bedos J-P, Varon E, Porcher R, Asfar P, Le Tulzo Y, Megarbane B, et al. Host-pathogen interactions and prognosis of critically ill immunocompetent patients with pneumococcal pneumonia: the nationwide prospective observational STREPTOGENE study. Intensive Care Med. 2018;44:2162–2173.

 12. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 2003;29:530–538.

- 13. Gotts JE, Matthay MA. Sepsis: pathophysiology and clinical management. BMJ. 2016;353:i1585.
- 14. Cavaillon J-M, Singer M, Skirecki T. Sepsis therapies: learning from 30 years of failure of translational research to propose new leads. EMBO Mol Med. 2020;12:e10128.

15. Scicluna BP, van Vught LA, Zwinderman AH, Wiewel MA, Davenport EE, Burnham KL,

et al. Classification of patients with sepsis according to blood genomic endotype: a prospective

cohort study. Lancet Respir Med. 2017;5:816–826.

16. Prescott HC, Calfee CS, Thompson BT, Angus DC, Liu VX. Toward Smarter Lumping and

Smarter Splitting: Rethinking Strategies for Sepsis and Acute Respiratory Distress Syndrome

Clinical Trial Design. Am J Respir Crit Care Med. 2016;194:147–155.

 17. Vincent J-L, Francois B, Zabolotskikh I, Daga MK, Lascarrou J-B, Kirov MY, et al. Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis- Associated Coagulopathy: The SCARLET Randomized Clinical Trial. JAMA. 2019;321:1993– 2002.

 18. Francois B, Jeannet R, Daix T, Walton AH, Shotwell MS, Unsinger J, et al. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight. 2018;3:e98960.

 19. Dupuy A-M, Philippart F, Péan Y, Lasocki S, Charles P-E, Chalumeau M, et al. Role of biomarkers in the management of antibiotic therapy: an expert panel review: I - currently available biomarkers for clinical use in acute infections. Ann Intensive Care. 2013;3:22.

 20. Miller RR, Lopansri BK, Burke JP, Levy M, Opal S, Rothman RE, et al. Validation of a Host Response Assay, SeptiCyte LAB, for Discriminating Sepsis from Systemic Inflammatory Response Syndrome in the ICU. Am J Respir Crit Care Med. 2018;198:903–913.

 21. Parlato M, Philippart F, Rouquette A, Moucadel V, Puchois V, Blein S, et al. Circulating biomarkers may be unable to detect infection at the early phase of sepsis in ICU patients: the CAPTAIN prospective multicenter cohort study. Intensive Care Medicine. 2018;44:1061– 1070.

- 22. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The
- Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement:
- guidelines for reporting observational studies. Ann Intern Med. 2007;147:573–577.
- 23. Parlato M, Cavaillon J-M. Host response biomarkers in the diagnosis of sepsis: a general
- overview. Methods Mol Biol. 2015;1237:149–211.
- 24. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J. qBase relative

quantification framework and software for management and automated analysis of real-time

- quantitative PCR data. Genome Biol. 2007;8:R19.
- 25. Marshall JC. The PIRO (predisposition, insult, response, organ dysfunction) model: toward a staging system for acute illness. Virulence. 2014;5:27–35.
- 26. Cohen J, Vincent J-L, Adhikari NKJ, Machado FR, Angus DC, Calandra T, et al. Sepsis: a roadmap for future research. Lancet Infect Dis. 2015;15:581–614.
- 530 27. IDSA Practice Guidelines. Available from: http://www.idsociety.org/PracticeGuidelines/?q=&ref=taxonomy\_map%3B(%22%2FIDSA% 2FSite+Map%2FGuidelines%2FPatient+Care%2FIDSA+Practice+Guidelines%2FInfections+ By+Organ+System-81567%2FLower%2FUpper+Respiratory%22)%3BOrgan+System.
- Accessed 15 Feb 2018.
- 28. Coste J, Bouée S, Ecosse E, Leplège A, Pouchot J. Methodological issues in determining the dimensionality of composite health measures using principal component analysis: case illustration and suggestions for practice. Qual Life Res. 2005;14:641–654.
- 29. Everitt BS. Unresolved Problems in Cluster Analysis. Biometrics. 1979;35:169–181.

 30. Wastell DG, Gray R. The numerical approach to classification: a medical application to develop a typology for facial pain. Stat Med. 1987;6:137–146.

 31. DeMerle KM, Angus DC, Baillie JK, Brant E, Calfee CS, Carcillo J, et al. Sepsis Subclasses: A Framework for Development and Interpretation. Crit Care Med. 2021;49:748– 759.

 32. Wong HR, Cvijanovich N, Lin R, Allen GL, Thomas NJ, Willson DF, et al. Identification of pediatric septic shock subclasses based on genome-wide expression profiling. BMC Med. 2009;7:34.

33. Davenport EE, Burnham KL, Radhakrishnan J, Humburg P, Hutton P, Mills TC, et al.

 Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med. 2016;4:259–271.

34. Sweeney TE, Azad TD, Donato M, Haynes WA, Perumal TM, Henao R, et al. Unsupervised

Analysis of Transcriptomics in Bacterial Sepsis Across Multiple Datasets Reveals Three Robust

Clusters. Crit Care Med. 2018;46:915–925.

 35. Omorou AY, Coste J, Escalon H, Vuillemin A. Patterns of physical activity and sedentary behaviour in the general population in France: cluster analysis with personal and socioeconomic correlates. J Public Health (Oxf). 2016;38:483–492.

## **Supporting information**

 **S1 Table. STROBE—Checklist of items that should be included in reports of** *cohort studies.* An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE



#### **S1 Fig. Distribution of missing values and determination of the cut-off to create binary**

- **variables.** Lower part of the figure: category of the value of each biomarker for each patient.
- Color code: white: value between the LLoQ and the ULoQ ; orange = value under the LLoQ;
- 586 blue = value over the ULoQ; grey = undetermined value.
- X axis: biomarkers
- Y axis: patients
- Upper part of the figure:
- Y axis: percentage of patients with a value below the LLoQ
- The plain blue line indicates the separation between biomarkers treated as binary variables (left
- side of the line) and as continuous variables (right side of the line). The dotted line indicates
- the cut-off of 40%, over which the biomarker was treated as a binary value.



# Figure 1

#### Cluster #5 (5% of the patients)



#### Cluster #1 (42 % of the patients)

Cluster #6 (5% of the patients)

Rare renal and hemodynamic support No pro-inflammatory mediators No anti-inflammatory mediators

# Figure 2